Related by context. All words. (Click for frequent words.) 74 kidney function 67 serum creatinine 67 hepatic function 66 renal dysfunction 64 systolic function 64 LVEF 64 beta blocker therapy 64 serum potassium 64 albuminuria 63 lung function 63 proteinuria 63 renal insufficiency 63 ventricular function 63 transaminase levels 63 serum calcium levels 63 serum sodium 62 glomerular filtration rate 62 liver histology 62 microalbuminuria 62 QTc interval 62 serum phosphate levels 62 eGFR 62 left ventricular systolic 62 serum creatinine levels 62 BYSTOLIC 62 posttransplant 62 β blockers 62 neurocognitive function 62 serum phosphate 62 bone resorption 61 Hb levels 61 hemodynamics 61 glomerular filtration 61 glycemia 61 renal impairment 61 hypotensive 61 severe renal impairment 61 creatinine clearance 61 hemoglobin Hb 61 coadministration 61 glucose tolerance 61 serum glucose 60 NPH insulin 60 HbA1c levels 60 CrCl 60 AST ALT 60 adrenal function 60 lipid levels 60 serum calcium 60 hypomagnesemia 60 platelet function 60 serum concentrations 60 endothelial function 60 estimated glomerular filtration 60 antihypertensive therapy 60 hemodynamic 60 myocardial 60 left ventricular dysfunction 60 QTc 60 alanine aminotransferase 60 thyroid stimulating hormone 60 aminotransferases 59 serum albumin 59 serum lipid levels 59 loop diuretics 59 systemic corticosteroids 59 aspartate aminotransferase AST 59 thyroxine 59 ATACAND 59 concomitant medications 59 creatinine levels 59 insulin sensitivity 59 PSADT 59 glucose homeostasis 59 endothelial dysfunction 59 plasma pharmacokinetics 59 serum cortisol 59 coronary revascularization 59 nicardipine 59 Secondary endpoints 59 insulin detemir 59 hepatic impairment 59 anticoagulation 59 disease progression 59 nephrotoxicity 59 intravenous diuretics 59 T2DM 59 left ventricular LV 59 serum phosphorus 59 afterload 59 QTc prolongation 59 nephropathy 59 antihypertensive medications 59 hepatotoxicity 59 metabolic parameters 59 antibiotic prophylaxis 59 cerebral perfusion 58 periprocedural 58 urinary albumin 58 tiotropium 58 inotropic 58 subclinical hypothyroidism 58 cirrhotic patients 58 leukocyte count 58 mucosal healing 58 virologic response 58 Postoperative 58 pulmonary capillary wedge 58 CsA 58 plasma uric acid 58 hepatic insufficiency 58 antiarrhythmic drugs 58 alteplase 58 calcium supplementation 58 immunosuppressive regimen 58 thrombotic events 58 platelet activation 58 natriuresis 58 plasma glucose 58 myocardial ischemia 58 CD4 + cell 58 potassium sparing diuretics 58 BENICAR HCT 58 serum testosterone 58 leukocyte counts 58 fasting plasma glucose 58 Serum creatinine 58 elevated creatinine 58 neurodevelopmental outcome 58 aldosterone 58 irbesartan 58 comorbidities 58 paricalcitol 58 metabolic acidosis 58 VAPRISOL 58 endothelial activation 58 SHPT 58 carotid IMT 58 hemolysis 58 serum PSA 58 serum cholesterol 58 candesartan 58 MULTAQ 58 hemoglobin concentrations 58 D dimer 58 pioglitazone 58 thrombotic complications 58 vasopressor 58 fondaparinux 58 cognitive function 58 SCr 58 serum lipid 58 allopurinol 58 elevated serum creatinine 58 colorectal adenoma 57 adiponectin levels 57 platelet reactivity 57 thyroid function 57 hemodilution 57 thiazide diuretics 57 glycemic control 57 postoperative mortality 57 hyperglycemia 57 myelosuppression 57 lipid profiles 57 IFN beta 57 LV ejection fraction 57 myocardial reperfusion 57 pharmacodynamic 57 HSCT 57 hypocalcemia 57 aldosterone antagonists 57 sunitinib 57 salivary flow 57 glycated hemoglobin levels 57 hyperparathyroidism 57 procalcitonin 57 glucocorticoid 57 blood glucose concentrations 57 mycophenolate mofetil 57 fosamprenavir 57 vasodilatation 57 hepatic enzymes 57 adalimumab 57 Pioglitazone 57 metastatic RCC 57 olmesartan 57 hematological parameters 57 hyperkalemia 57 tumor lysis syndrome 57 glycosylated hemoglobin HbA1c 57 colorectal liver metastases 57 serum phosphorous 57 hepatorenal syndrome 57 glycosylated hemoglobin levels 57 dobutamine 57 hyperglycaemia 57 HbA 1c levels 57 left ventricular ejection 57 intima media thickness 57 OADs 57 candesartan cilexetil 57 hepatic 57 glargine 57 elevated LDH 57 systolic BP 57 neoadjuvant chemotherapy 57 platelet counts 57 thyroid hormone levels 57 antiplatelet therapy 57 aspartate aminotransferase 57 plasma concentrations 57 inflammatory markers 57 neurologic outcomes 57 atazanavir 57 posaconazole 57 tacrolimus 57 anticoagulant therapy 57 echocardiographic 57 glomerular 57 bosentan 57 imatinib therapy 57 lactate dehydrogenase LDH 57 NATRECOR R 57 endometrial hyperplasia 57 systemic corticosteroid 57 serum uric acid 57 inotropic agents 57 hemoglobin concentration 57 hypercalcemia 57 cytopenias 57 pulmonary exacerbations 57 perioperatively 57 APTIVUS r 57 serum PTH 57 fibrinolysis 57 pulmonary function 57 serum potassium levels 57 biochemical recurrence 57 DAPT 57 parathyroidectomy 56 extrapyramidal symptoms 56 androgen deprivation 56 agonist induced 56 mixed hyperlipidemia 56 corticosteroid therapy 56 eplerenone 56 skeletal muscle mass 56 urinary calcium 56 ovarian function 56 severe renal insufficiency 56 rFVIIa 56 neuronal function 56 ejection fractions 56 triglyceride levels 56 NT proBNP 56 biochemical relapse 56 moderate renal impairment 56 creatinine 56 physiologic 56 renal artery stenosis 56 plasma lipids 56 comorbid conditions 56 alanine aminotransferase ALT 56 vasodilators 56 prognostic variables 56 intact parathyroid hormone 56 EDARBI 56 postoperative complication 56 HIV HCV coinfected 56 Natalizumab 56 FEV1 56 PREZISTA r 56 nonfatal MI 56 viral load 56 bioprosthetic valve 56 CK MB 56 macroalbuminuria 56 verapamil 56 EXJADE 56 pharmacodynamic PD 56 lumbar spine bone 56 nondiabetic patients 56 sirolimus 56 hypokalemia 56 primary aldosteronism 56 virologic failure 56 triglyceride concentrations 56 atherogenic dyslipidemia 56 platelet aggregation 56 serum aminotransferase levels 56 tolvaptan 56 diastolic dysfunction 56 hypervolemic hyponatremia 56 hematologic parameters 56 oral antidiabetic medication 56 systolic dysfunction 56 β cell 56 cTnI 56 rhTSH 56 reperfusion 56 postoperative AF 56 ischemia 56 euthyroid 56 GnRH agonists 56 thyrotoxicosis 56 NIHSS score 56 ischemic cardiomyopathy 56 myocardial infarction 56 sinus rhythm 56 OPCAB 56 overt nephropathy 56 serum IGF 56 infarct size 56 radioiodine therapy 56 lactic acidosis 56 aminotransferase levels 56 prognostic factors 56 tirofiban 56 HBeAg 56 reinfarction 56 hsCRP levels 56 NATRECOR ® 56 tumor recurrence 56 Hb A1C 56 QTc intervals 56 biodistribution 56 thrombocytopenic 56 antidiabetic therapy 56 CD4 cell 56 serum testosterone levels 56 Candesartan 56 preoperative chemotherapy 56 bypass grafting 56 fibrinolytic 56 cinacalcet 56 captopril 56 serum HBV DNA 56 serum vitamin D 56 systemic hypotension 56 cystatin C 56 intravascular volume 56 tamsulosin 56 normotensive 56 plasma renin activity 56 TNFalpha 56 bezafibrate 56 metastatic renal cell carcinoma 56 dosage regimens 56 haemodynamic 56 serum ALT 56 ß blockers 56 atrioventricular block 56 perioperative morbidity 56 hyperphosphatemia 56 prospectively defined 56 myocardial viability 56 pretransplant 56 triiodothyronine 56 PSA nadir 56 retransplantation 56 CD4 + 56 prognostic significance 55 levodopa 55 graft patency 55 tissue oxygenation 55 inflammatory biomarkers 55 virological response 55 oral anticoagulant therapy 55 lipid parameters 55 vascular reactivity 55 hypotension 55 Hb 55 retinal thickness 55 recurrent ischemia 55 Hematologic 55 HbA 1c 55 peptide BNP 55 ursodeoxycholic acid 55 growth hormone secretion 55 pulmonary arterial 55 Primary endpoints 55 parkinsonian symptoms 55 nesiritide 55 Insulin sensitivity 55 LATUDA 55 HPA axis 55 MELD scores 55 PCa 55 IUGR 55 cyclosporine 55 intracoronary 55 mild renal insufficiency 55 perioperative complications 55 thromboembolic events 55 paraprotein 55 pharmacokinetic profile 55 hyperoxia 55 plasma triglycerides 55 hypoperfusion 55 histologic 55 contractile function 55 ACh 55 HMG CoA reductase inhibitors 55 calculated creatinine clearance 55 myopathy rhabdomyolysis 55 lispro 55 inducible nitric oxide synthase 55 euvolemic 55 symptomatic hypotension 55 adenomatous 55 hepatic fibrosis 55 antioxidant supplementation 55 myocardial perfusion 55 reperfusion therapy 55 adrenal suppression 55 antiarrhythmic drug 55 sperm motility 55 H. pylori infection 55 plasma lipoprotein 55 tolerability 55 lymphocyte counts 55 albumin excretion 55 oral antidiabetes 55 osmolality 55 ascites 55 Akt activation 55 lipid lowering therapy 55 thiazide 55 drug eluting stent implantation 55 FOLFOX4 55 CD# + [002] 55 T1DM 55 impaired renal 55 immunosuppressive agents 55 hemoglobin A1c levels 55 artery stenosis 55 Lp PLA2 55 ABCB1 55 GH deficiency 55 antitumor efficacy 55 thrombocytosis 55 CYP#C# [001] 55 azacitidine 55 parathyroid hormone PTH 55 preserved ejection fraction 55 LVSD 55 vWF 55 hypovolemic 55 undergoing coronary artery 55 vascular permeability 55 coagulopathy 55 vandetanib 55 surrogate endpoint 55 systolic hypertension 55 coagulation parameters 55 Kaplan Meier analysis 55 platelet inhibition 55 urinary oxalate 55 ciclosporin 55 blood lipids 55 phosphate binders 55 HIV RNA 55 natriuretic peptides 55 postoperative pulmonary 55 mL/min/#.# m 2 55 nondiabetics 55 leukocyte 55 intestinal permeability 55 neurologic progression 55 kidney dysfunction 55 NSTE ACS 55 inotropes 55 Lp PLA 2 55 viral suppression 55 mL/min/#.# m2 55 ventricular dysfunction 55 impaired hepatic 55 renal allograft 55 MADRS score 55 Proteinuria 55 HbA1C 55 triacylglycerol 55 urinary albumin excretion 55 nonischemic 55 anti Xa 55 K ras mutations 55 pharmacokinetics 55 neurohormonal activation 55 mRNA expression 55 c reactive protein 55 cardiovascular mortality 55 EDSS scores 55 orthostatic hypotension 55 fasting glucose 55 glycosylated hemoglobin 55 antihypertensive medication 55 ejection fraction 55 mRCC 55 urinary protein 55 Hydroxyurea 55 perioperative mortality 55 erythropoietic 55 iPTH 55 AVANDIA 55 4mg/kg 55 isoenzyme 55 GnRH agonist 55 preoperative 55 urocortin 2 55 L thyroxine 55 FOSRENOL ® 55 postmenopausal estrogen 55 Cmax 55 hemodynamic parameters 55 nephrotoxic drugs 55 DMARD 55 endothelial 55 carotid stenosis 55 unfractionated heparin 55 thienopyridine 55 hypertensives 55 warfarin therapy 55 QT intervals 55 fasting insulin 55 hepatic dysfunction 55 steatosis 55 adverse cytogenetics 55 neurodevelopmental outcomes 55 oral anticoagulation 55 HBeAg seroconversion 55 dystrophin expression 55 thyroid hormone 55 autoregulation 55 levodopa carbidopa 55 antiangiogenic therapy 54 Atacand 54 BH4 54 flecainide 54 cerebral oxygenation 54 transaminases 54 hematologic toxicity 54 hypogonadal men 54 FDG PET 54 CMV disease 54 C1 INH 54 neutrophil count 54 calcitriol 54 ventilatory 54 troponin T 54 serum triglyceride levels 54 adrenal insufficiency 54 symptomatic VTE 54 nonoperative treatment 54 endotoxemia 54 p# activation 54 osteoblast 54 immunosuppression 54 statin therapy 54 glucose intolerance 54 liver transplant recipients 54 genotypic resistance 54 urinary symptoms 54 postprocedure 54 calcineurin inhibitors 54 co morbidities 54 subcutaneously injected 54 cardiovascular morbidity 54 postoperative 54 diuresis 54 posttreatment 54 REOPRO 54 immune reconstitution 54 nocturnal hypoglycaemia 54 Hemolysis 54 postoperative morbidity 54 diastolic function 54 erectile function 54 cardiogenic shock 54 baroreflex 54 fractional shortening 54 benazepril 54 prostate cancer CaP 54 hemodialysis patients 54 heparin induced thrombocytopenia 54 fasting glucose levels 54 decompensated heart failure 54 serum bicarbonate 54 INCB# [003] 54 steroid dexamethasone 54 thrombus formation 54 antiplatelet drugs 54 sustained virological response 54 neuroleptics 54 insulin glargine 54 intravenous bisphosphonates 54 prolactin levels 54 fatal myocardial infarction 54 riociguat 54 thromboembolism 54 cART 54 autonomic dysfunction 54 ketorolac 54 NAbs 54 radiotherapy RT 54 myocardial contractility 54 peginterferon 54 Secondary endpoints include 54 transgene expression 54 aortic valve stenosis 54 LEXIVA 54 DMARDs 54 severe neutropenia 54 LV dysfunction 54 diabetic kidney 54 Secondary endpoints included 54 HBV infection 54 myelosuppressive 54 pharmacodynamic effects 54 homocysteine concentrations 54 gemcitabine 54 tiotropium bromide 54 anticoagulation therapy 54 cardiovascular calcification 54 revascularization procedures 54 decitabine 54 salmeterol HFA MDI 54 LV systolic function 54 hypercalciuria 54 elevated triglyceride levels 54 levodopa therapy 54 hyperphenylalaninemia HPA due 54 serum urate 54 nonfatal myocardial infarction 54 liver transaminases 54 pituitary hormone 54 surrogate markers 54 immunomodulatory therapy 54 lung epithelium 54 clopidogrel 54 free survival PFS 54 blood Phe levels 54 alpha blocker 54 arterial stiffness 54 ischemic 54 cardiac toxicity 54 anti leukemic 54 DHCA 54 interferon therapy 54 intraventricular 54 Tolerability 54 rHuPH# 54 lipid lowering agents 54 pharmacokinetics PK 54 liver dysfunction 54 atheroma volume 54 serum magnesium 54 haematopoietic 54 P = .# 54 blood glucose levels 54 cardiac dysfunction 54 β blocker 54 immunomodulation 54 mitral stenosis 54 rituximab 54 bypass graft CABG surgery 54 opioid analgesia 54 liver metastasis 54 aripiprazole 54 baseline HbA1c 54 spironolactone 54 potentially hepatotoxic 54 morphologic 54 macrovascular 54 plasma folate 54 intraocular pressure IOP 54 mIU L 54 eptifibatide 54 sinus bradycardia 54 protein excretion 54 magnesium intake 54 mutated KRAS 54 glucose metabolism 54 cellularity 54 serum sodium levels 54 intra articular injection 54 resynchronization therapy 54 adrenocorticotropic hormone 54 CTEPH 54 NGAL 54 HAART regimen 54 antihypertensive drugs 54 elevated ALT 54 chemoradiotherapy 54 rhGH 54 Microalbuminuria 54 neutrophil counts 54 pharmacokinetic profiles 54 central corneal thickness 54 pharmacodynamic parameters 54 atherosclerotic lesions 54 diabetes mellitus 54 plasma fibrinogen 54 ACTOplus met 54 abciximab 54 anti coagulant therapy 54 corrected QT interval 54 PNH patients 54 certolizumab 54 IV bisphosphonates 54 cranial irradiation 54 glucose lowering 54 virologic 54 multivariable analysis 54 chronic hemodialysis 54 exhaled nitric oxide 54 gout flares 54 C reactive protein 54 eculizumab therapy 54 intravesical 54 parathyroid hormone 54 milrinone 54 serum ferritin 54 dysfunction LVSD 54 intracranial hemorrhage ICH 54 troponin 54 adjuvant chemotherapy 54 preoperatively 54 CMV infection 54 nephrotoxic 54 DMARDS 54 left ventricular hypertrophy 54 renal transplantation 54 μmol L 54 therapeutic regimens 54 advanced adenoma 54 GH secretion 54 ISTODAX 54 #mg dose [001] 54 HRQOL 54 rt PA 54 ribavirin therapy 54 acute humoral rejection 54 hemoglobin A1C 54 adenoma 54 cardiorespiratory fitness 54 thromboembolic disease 54 subgroup analyzes 54 μg kg 54 lymph node metastasis 54 baroreflex sensitivity 54 sinus node dysfunction 54 microvascular complications 54 acute coronary syndromes 54 F FDG PET 54 urinary excretion 54 onset diabetes mellitus 54 progression TTP 54 antidiabetic medications 54 intermittent hemodialysis 54 COREG 54 invasive aspergillosis 54 cytoreductive nephrectomy 53 carotid intima media 53 cobalamin 53 HCV RNA 53 ventricular remodeling 53 serum estradiol 53 selenium supplementation 53 sotalol 53 myocardial infarction stroke 53 ADCS ADL 53 LV hypertrophy 53 ALND 53 pulmonary artery banding 53 baroreceptor 53 fasting blood glucose 53 postoperatively 53 cardiac troponin 53 liver enzymes 53 hyperoxaluria 53 chemosensitivity 53 renal 53 urate levels 53 aspirin clopidogrel 53 KCNE2 53 pressor response 53 voriconazole 53 thromboembolic 53 SGPT 53 antithrombotic therapy 53 HBV DNA 53 bone marrow reticulin 53 fatty acid oxidation 53 undergoing peritoneal dialysis 53 iron overload 53 hemoglobin A1c HbA1c 53 lumbar spine BMD 53 sirolimus eluting stents 53 DLTs 53 neovascularization 53 IFN gamma 53 mineral density 53 hepatic enzyme 53 antidiabetic drugs 53 obstructive CAD 53 plasma leptin 53 androgen deprivation therapy 53 aldosterone antagonist 53 COPD exacerbations 53 urodynamic 53 left ventricular diastolic 53 antithrombotic 53 5FU 53 insulin secretion 53 leucocyte 53 myopathy 53 thromboembolic complications 53 bisphosphonate therapy 53 isolated systolic hypertension 53 alkaline phosphatase 53 mg BID 53 HBsAg 53 International Prostate Symptom 53 fulvestrant 53 MMSE scores 53 thyrotropin 53 hepatic metastases 53 hsCRP 53 remyelination 53 antigen PSA levels 53 dysglycemia 53 Adalimumab 53 spermatogenesis 53 locoregional 53 thrombolytics 53 mucociliary clearance 53 adefovir 53 multivariate Cox 53 metabolite concentrations 53 Elitek 53 VTE prophylaxis 53 docetaxel chemotherapy 53 tHcy 53 umbilical vein 53 HMG CoA reductase inhibitor 53 intermittent dosing 53 HBV infections 53 primary hypercholesterolemia 53 elevated IOP 53 HAART regimens 53 octreotide 53 HF hospitalization 53 prostate cancer PCa 53 nitroprusside 53 flutamide 53 thromboprophylaxis 53 moderate hepatic impairment 53 VT VF 53 dyslipidaemia 53 hepatic toxicity 53 pCR 53 dopaminergic therapy 53 pamidronate 53 valproate 53 graft occlusion 53 HOMA IR 53 Pharmacokinetic 53 troponins 53 administered subcutaneously 53 triacylglycerol concentrations 53 plasma homocysteine 53 amnestic mild cognitive impairment 53 reflux symptoms 53 HAART 53 angiotensin receptor blockers 53 electrolyte abnormalities 53 histological subtype 53 acute decompensation 53 neuroleptic 53 transaminase elevations 53 microcirculation 53 receiving VELCADE 53 Androxal TM 53 EBRT 53 estimated GFR 53 glatiramer acetate 53 oxygen saturations 53 pharmacokinetic characteristics 53 serum leptin 53 definite stent thrombosis 53 cTnT 53 KRAS mutant tumors 53 lipid lowering drugs 53 daunorubicin 53 ACE inhibitor ramipril 53 elevated LDL cholesterol 53 ADAS Cog 53 VIIBRYD 53 lactate dehydrogenase 53 serum phosphorus levels 53 prostate cancer CRPC 53 immunosuppressive medications 53 metastatic malignant 53 PAOD 53 NNT = 53 TMP SMX 53 intratumoral 53 L PPDS 53 hydroxyvitamin D levels 53 iNOS 53 cardiac repolarization 53 severe exacerbations 53 microvascular disease 53 SGOT 53 #mg/day [002] 53 pancreatic insufficiency 53 refractory NSCLC 53 hypertonic saline 53 monotherapy 53 biochemical markers 53 PaO 2 53 vasodilation 53 asthma exacerbations 53 airflow obstruction 53 pg ml 53 resected pancreatic cancer 53 gut motility 53 renoprotective 53 abdominal adiposity 53 cardiac conduction 53 indomethacin 53 IGFBP 3 53 specific antigen PSA 53 cirrhotic 53 bronchodilation 53 hepatic glucose production 53 prostate specific antigen 53 pharmacodynamics PD 53 neostigmine 53 gastric emptying 53 collagen synthesis 53 epoetin alfa 53 PlGF 53 Telintra 53 antiplatelet medications 53 pharmacokinetic PK 53 primidone 53 PBMCs 53 HbA1c 53 QT QTc interval 53 autoantibody levels 53 neurocognitive outcomes 53 docetaxel 53 lung fibrosis 53 CLA supplementation 53 tHcy concentrations 53 renal fibrosis 53 platelet inhibitor 53 cytoreductive surgery 53 urinary retention 53 metformin sulfonylurea 53 curative resection 53 prothrombin 53 immunosuppressive medication 53 amenorrhoea 53 engraftment 53 myocardial tissue 53 IFN α 53 weekly subcutaneous injections 53 acute myocardial infarction 53 plasma creatinine 53 symptomatic intracranial 53 liver fibrosis 53 Myelosuppression 53 mitoxantrone 53 poor metabolizers 53 calcium phosphorus 53 pharmacokinetic interactions 53 anastomotic leak 53 occlusive disease 53 systolic 53 vascularization 53 coronary perfusion 53 timepoint 53 methotrexate 53 symptom severity 53 temsirolimus 53 inotropic therapy 53 angiotensin converting enzyme ACE 53 divalproex sodium 53 pro angiogenic 53 erlotinib Tarceva ® 53 advanced neoplasia 53 IV NSCLC 53 acute GvHD 53 prednisone prednisolone 53 danazol 53 KOMBIGLYZE XR